N.J. Jury Assesses $2.62M Against Roche in Accutane Trial

A New Jersey jury has assessed $2.62 million in damages against Hoffmann-La Roche Inc. and its Swiss parent company in the first of 400 suits to be tried over the acne drug Accutane's propensity to cause inflammatory bowel disease. However, the jury did not award punitive damages under the state's Consumer Fraud Act, because it found insufficient evidence that the manufacturer intentionally failed to warn that the drug can cause IBD.

This article requires premium access

This article requires premium access to Law.com. Please sign in or subscribe to read the full text.